An immunohistochemical panel to distinguish ovarian from uterine serous papillary carcinomas

Yaxia Zhang, Monica Garcia-Buitrago, Tulay Sengul, Samer Schuman, Parvin Ganjei-Azar

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Serous papillary carcinomas (SPCs) share a similar morphology regardless of whether they originate from the ovary or the uterus. Identification of the site of origin of the tumor can be a challenging and a diagnostic dilemma, particularly, in the setting of a pelvic mass or peritoneal carcinomatosis. Recognition of the site of origin influences the staging, management, and prognosis of these malignancies. The purpose of this study is to identify a panel of markers to distinguish the ovarian serous papillary carcinomas (OSPC) from the uterine serous papillary carcinomas (USPC). Formalin-fixed, paraffin-embedded archival tissue from 46 cases of SPCs (33 uterine and 13 ovarian) were stained using antibodies for estrogen receptor (ER), WT1, insulin-like growth factor-II mRNA-binding protein 3 (IMP3), p53, and p16. The OSPC expressed ER (92%), WT1 (100%), IMP3 (92%), p53 (92%), and p16 (92%). The USPCs expressed ER (30%), WT1 (64%), IMP3 (85%), p53 (64%), and p16 (76%). Only ER expression was significantly higher in OSPC compared with USPCs (P<0.001). The combined ERWT1 phenotype was present in 92% of the OSPC, whereas only 18% of the USPCs had the same phenotype (P<0.001). Furthermore, 71% of the OSPCs expressed ER, p53, WT1, IMP3, and p16 immunophenotype, whereas in USPCs, the tumor cells showed immunophenotypic diversity, with only 6% of the USPCs expressing reactivity to all the 5 markers (P<0.001). This study suggests that ER alone or in combination with a limited panel of markers may be used to identify the site of origin of SPCs.

Original languageEnglish
Pages (from-to)476-481
Number of pages6
JournalInternational Journal of Gynecological Pathology
Volume32
Issue number5
DOIs
StatePublished - Sep 1 2013
Externally publishedYes

Fingerprint

Papillary Carcinoma
Estrogen Receptors
Carrier Proteins
Messenger RNA
Phenotype
Neoplasms
Insulin-Like Growth Factor II
Paraffin
Formaldehyde
Uterus
Ovary
Carcinoma
Antibodies

Keywords

  • ER
  • IMP3
  • Ovarian
  • p16
  • p53
  • Serous papillary carcinoma
  • Uterine
  • WT1

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Obstetrics and Gynecology

Cite this

An immunohistochemical panel to distinguish ovarian from uterine serous papillary carcinomas. / Zhang, Yaxia; Garcia-Buitrago, Monica; Sengul, Tulay; Schuman, Samer; Ganjei-Azar, Parvin.

In: International Journal of Gynecological Pathology, Vol. 32, No. 5, 01.09.2013, p. 476-481.

Research output: Contribution to journalArticle

@article{445b9876631c41a29e54742740d7a0a9,
title = "An immunohistochemical panel to distinguish ovarian from uterine serous papillary carcinomas",
abstract = "Serous papillary carcinomas (SPCs) share a similar morphology regardless of whether they originate from the ovary or the uterus. Identification of the site of origin of the tumor can be a challenging and a diagnostic dilemma, particularly, in the setting of a pelvic mass or peritoneal carcinomatosis. Recognition of the site of origin influences the staging, management, and prognosis of these malignancies. The purpose of this study is to identify a panel of markers to distinguish the ovarian serous papillary carcinomas (OSPC) from the uterine serous papillary carcinomas (USPC). Formalin-fixed, paraffin-embedded archival tissue from 46 cases of SPCs (33 uterine and 13 ovarian) were stained using antibodies for estrogen receptor (ER), WT1, insulin-like growth factor-II mRNA-binding protein 3 (IMP3), p53, and p16. The OSPC expressed ER (92{\%}), WT1 (100{\%}), IMP3 (92{\%}), p53 (92{\%}), and p16 (92{\%}). The USPCs expressed ER (30{\%}), WT1 (64{\%}), IMP3 (85{\%}), p53 (64{\%}), and p16 (76{\%}). Only ER expression was significantly higher in OSPC compared with USPCs (P<0.001). The combined ERWT1 phenotype was present in 92{\%} of the OSPC, whereas only 18{\%} of the USPCs had the same phenotype (P<0.001). Furthermore, 71{\%} of the OSPCs expressed ER, p53, WT1, IMP3, and p16 immunophenotype, whereas in USPCs, the tumor cells showed immunophenotypic diversity, with only 6{\%} of the USPCs expressing reactivity to all the 5 markers (P<0.001). This study suggests that ER alone or in combination with a limited panel of markers may be used to identify the site of origin of SPCs.",
keywords = "ER, IMP3, Ovarian, p16, p53, Serous papillary carcinoma, Uterine, WT1",
author = "Yaxia Zhang and Monica Garcia-Buitrago and Tulay Sengul and Samer Schuman and Parvin Ganjei-Azar",
year = "2013",
month = "9",
day = "1",
doi = "10.1097/PGP.0b013e31826ddc4e",
language = "English",
volume = "32",
pages = "476--481",
journal = "International Journal of Gynecological Pathology",
issn = "0277-1691",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - An immunohistochemical panel to distinguish ovarian from uterine serous papillary carcinomas

AU - Zhang, Yaxia

AU - Garcia-Buitrago, Monica

AU - Sengul, Tulay

AU - Schuman, Samer

AU - Ganjei-Azar, Parvin

PY - 2013/9/1

Y1 - 2013/9/1

N2 - Serous papillary carcinomas (SPCs) share a similar morphology regardless of whether they originate from the ovary or the uterus. Identification of the site of origin of the tumor can be a challenging and a diagnostic dilemma, particularly, in the setting of a pelvic mass or peritoneal carcinomatosis. Recognition of the site of origin influences the staging, management, and prognosis of these malignancies. The purpose of this study is to identify a panel of markers to distinguish the ovarian serous papillary carcinomas (OSPC) from the uterine serous papillary carcinomas (USPC). Formalin-fixed, paraffin-embedded archival tissue from 46 cases of SPCs (33 uterine and 13 ovarian) were stained using antibodies for estrogen receptor (ER), WT1, insulin-like growth factor-II mRNA-binding protein 3 (IMP3), p53, and p16. The OSPC expressed ER (92%), WT1 (100%), IMP3 (92%), p53 (92%), and p16 (92%). The USPCs expressed ER (30%), WT1 (64%), IMP3 (85%), p53 (64%), and p16 (76%). Only ER expression was significantly higher in OSPC compared with USPCs (P<0.001). The combined ERWT1 phenotype was present in 92% of the OSPC, whereas only 18% of the USPCs had the same phenotype (P<0.001). Furthermore, 71% of the OSPCs expressed ER, p53, WT1, IMP3, and p16 immunophenotype, whereas in USPCs, the tumor cells showed immunophenotypic diversity, with only 6% of the USPCs expressing reactivity to all the 5 markers (P<0.001). This study suggests that ER alone or in combination with a limited panel of markers may be used to identify the site of origin of SPCs.

AB - Serous papillary carcinomas (SPCs) share a similar morphology regardless of whether they originate from the ovary or the uterus. Identification of the site of origin of the tumor can be a challenging and a diagnostic dilemma, particularly, in the setting of a pelvic mass or peritoneal carcinomatosis. Recognition of the site of origin influences the staging, management, and prognosis of these malignancies. The purpose of this study is to identify a panel of markers to distinguish the ovarian serous papillary carcinomas (OSPC) from the uterine serous papillary carcinomas (USPC). Formalin-fixed, paraffin-embedded archival tissue from 46 cases of SPCs (33 uterine and 13 ovarian) were stained using antibodies for estrogen receptor (ER), WT1, insulin-like growth factor-II mRNA-binding protein 3 (IMP3), p53, and p16. The OSPC expressed ER (92%), WT1 (100%), IMP3 (92%), p53 (92%), and p16 (92%). The USPCs expressed ER (30%), WT1 (64%), IMP3 (85%), p53 (64%), and p16 (76%). Only ER expression was significantly higher in OSPC compared with USPCs (P<0.001). The combined ERWT1 phenotype was present in 92% of the OSPC, whereas only 18% of the USPCs had the same phenotype (P<0.001). Furthermore, 71% of the OSPCs expressed ER, p53, WT1, IMP3, and p16 immunophenotype, whereas in USPCs, the tumor cells showed immunophenotypic diversity, with only 6% of the USPCs expressing reactivity to all the 5 markers (P<0.001). This study suggests that ER alone or in combination with a limited panel of markers may be used to identify the site of origin of SPCs.

KW - ER

KW - IMP3

KW - Ovarian

KW - p16

KW - p53

KW - Serous papillary carcinoma

KW - Uterine

KW - WT1

UR - http://www.scopus.com/inward/record.url?scp=84883454172&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883454172&partnerID=8YFLogxK

U2 - 10.1097/PGP.0b013e31826ddc4e

DO - 10.1097/PGP.0b013e31826ddc4e

M3 - Article

C2 - 23896709

AN - SCOPUS:84883454172

VL - 32

SP - 476

EP - 481

JO - International Journal of Gynecological Pathology

JF - International Journal of Gynecological Pathology

SN - 0277-1691

IS - 5

ER -